WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (RXi), a majority-owned subsidiary of CytRx Corporation (NASDAQ: CYTR), today announced that it has entered into an agreement with Thermo Fisher Scientific Inc. (NYSE: TMO), to exclusively license certain RNA interference (RNAi) sequences to an undisclosed number of target genes, with an initial focus in the areas of type 2 diabetes, obesity, neurology and oncology, for the ongoing development of RXi’s rxRNA™ compounds.
